461 related articles for article (PubMed ID: 15863798)
21. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
Ghanizadeh A; Nikseresht MS; Sahraian A
Schizophr Res; 2013 Jun; 147(1):110-115. PubMed ID: 23583010
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
[TBL] [Abstract][Full Text] [Related]
23. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
Smith IG; Goulder MA;
J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
[TBL] [Abstract][Full Text] [Related]
24. Effects of sibutramine treatment in obese adolescents: a randomized trial.
Berkowitz RI; Fujioka K; Daniels SR; Hoppin AG; Owen S; Perry AC; Sothern MS; Renz CL; Pirner MA; Walch JK; Jasinsky O; Hewkin AC; Blakesley VA;
Ann Intern Med; 2006 Jul; 145(2):81-90. PubMed ID: 16847290
[TBL] [Abstract][Full Text] [Related]
25. [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
Zhao Y; Wang X; Yan Z
Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Sep; 35(5):329-32. PubMed ID: 11769634
[TBL] [Abstract][Full Text] [Related]
26. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
27. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP;
Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
[TBL] [Abstract][Full Text] [Related]
28. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
31. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.
Kwon JS; Choi JS; Bahk WM; Yoon Kim C; Hyung Kim C; Chul Shin Y; Park BJ; Geun Oh C
J Clin Psychiatry; 2006 Apr; 67(4):547-53. PubMed ID: 16669719
[TBL] [Abstract][Full Text] [Related]
32. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
[TBL] [Abstract][Full Text] [Related]
33. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
McMahon FG; Fujioka K; Singh BN; Mendel CM; Rowe E; Rolston K; Johnson F; Mooradian AD
Arch Intern Med; 2000 Jul; 160(14):2185-91. PubMed ID: 10904462
[TBL] [Abstract][Full Text] [Related]
35. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Mathus-Vliegen EM;
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
[TBL] [Abstract][Full Text] [Related]
36. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A
Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318
[TBL] [Abstract][Full Text] [Related]
37. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
[TBL] [Abstract][Full Text] [Related]
38. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
McElroy SL; Winstanley E; Mori N; Martens B; McCoy J; Moeller D; Guerdjikova AI; Keck PE
J Clin Psychopharmacol; 2012 Apr; 32(2):165-72. PubMed ID: 22367654
[TBL] [Abstract][Full Text] [Related]
39. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
40. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]